©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Wortmannin-sensitive Trafficking Pathways in Chinese Hamster Ovary Cells
DIFFERENTIAL EFFECTS ON ENDOCYTOSIS AND LYSOSOMAL SORTING (*)

(Received for publication, November 28, 1995; and in revised form, January 23, 1996)

Jayme L. Martys (3)(§) Christina Wjasow(§) (1)(¶) Dawn M. Gangi (1) Margaret C. Kielian (2) Timothy E. McGraw (3) Jonathan M. Backer (1)(**)

From the  (1)Departments ofMolecular Pharmacology and (2)Cell Biology, Albert Einstein College of Medicine, Bronx, New York 10461 and the (3)Department of Pathology, College of Physicians and Surgeons, New York, New York 10032

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Phosphatidylinositol (PI) 3`-kinases are a family of lipid kinases implicated in the regulation of cell growth by oncogene products and tyrosine kinase growth factor receptors. The catalytic subunit of the p85/p110 PI 3`-kinase is homologous to VPS-34, a phosphatidylinositol-specific lipid kinase involved in the sorting of newly synthesized hydrolases to the yeast vacuole. This suggests that PI 3`-kinases may play analogous roles in mammalian cells. We have measured a number of secretory and endocytic trafficking events in Chinese hamster ovary cells in the presence of wortmannin, a potent inhibitor of PI 3`-kinase. Wortmannin caused a 40-50% down-regulation of surface transferrin receptors, with a dose dependence identical to that required for maximal inhibition of the p85/p110 PI 3`-kinase in intact cells. The redistribution of transferrin receptors reflected a 60% increase in the internalization rate and a 35% decrease in the recycling rate. Experiments with fluorescent transferrin showed that entry of transferrin receptors into the recycling compartment and efflux of receptors out of the compartment were slowed by wortmannin. Wortmannin altered the morphology of the recycling compartment, which was more vesiculated than in untreated cells. Using Semliki Forest virus as a probe, we also found that delivery of the endocytosed virus to its lysosomal site of degradation was slowed by wortmannin, whereas endosomal acidification was unaffected. In contrast to these effects on endocytosis and recycling, wortmannin did not affect intracellular processing of newly synthesized viral spike proteins. Wortmannin did induce missorting of the lysosomal enzyme cathepsin D to the secretory pathway, but only at a dose 20-fold greater than that required to inhibit p85/p110 PI 3`-kinase activity or to redistribute transferrin receptors. Our data demonstrate the presence of wortmannin-sensitive enzymes at three distinct steps of the endocytic cycle in Chinese hamster ovary cells: internalization, transit from early endosomes to the recycling and degradative compartments, and transit from the recycling compartment back to the cell surface. The wortmannin-sensitive enzymes critical for endocytosis and recycling are distinct from those involved in sorting newly synthesized lysosomal enzymes.


INTRODUCTION

Phosphatidylinositol (PI) (^1)3`-kinases are a family of lipid kinases that contain homologous catalytic domains, but distinct regulatory elements. The first known PI 3`-kinase was a heterodimeric lipid kinase composed of an 85-kDa regulatory subunit and a 110-kDa catalytic subunit(1, 2, 3, 4, 5) . This enzyme was discovered in transformed cells, but is also stimulated by mitogens including platelet-derived growth factor and insulin(6) . The p85/p110 PI 3`-kinase is activated when the two SH2 domains in p85 bind to phosphorylated YXXM motifs in tyrosine kinase receptors or their substrates(7, 8) ; activation by interactions with p21, Rho, and the SH3 domains of Src family kinases has also been described(9, 10, 11) . Activation of the p85/p110 PI 3`-kinase increases the intracellular concentrations of PI(3,4)P(2) and PI(3,4,5)P(3)(12) . Although these lipid products activate calcium-independent protein kinase C isoforms in vitro, their function in intact cells is not known(13, 14) . p110 also contains a serine/threonine protein kinase activity with an apparently limited range of substrates(15) . In addition to multiple isoforms of both the 85- and 110-kDa subunits, the recent description of several novel PI 3`-kinase isoforms with varying substrate specificities and regulatory mechanisms has added to the complexity of 3-phosphoinositide signaling(16, 17, 18) .

The p110 catalytic subunit is 55% homologous to the Saccharomyces cerevisiae protein VPS-34(2, 19) . Disruption of the VPS-34 gene causes missorting of vacuolar hydrolases to the secretory pathway and also abolishes PI 3`-kinase activity in yeast(20) . Although VPS-34 is a PI 3`-kinase, its substrate specificity is limited to phosphatidylinositol, unlike the p85/p110 mammalian enzyme that also utilizes PI(4)P and PI(4,5)P(2)(21) . Moreover, mammalian p110 is lethal when expressed in yeast(22) . However, a mammalian homologue to VPS-34 has been cloned, which, like VPS-34, is a lipid kinase activity specific for phosphatidylinositol (16) . Several experiments suggest that PI 3`-kinases play a role in vesicular trafficking in mammalian cells. Mutagenesis of the two PI 3`-kinase-binding sites in the platelet-derived growth factor receptor disrupts the post-endocytic sorting of this receptor(23) . However, these same sites bind to SH2-containing molecules other than PI 3`-kinase(24) , which complicates the interpretation of this finding. PI kinase inhibitors such as wortmannin and LY294002 inhibit histamine secretion in RBL-2H3 cells, exocytosis in neutrophils stimulated with chemotactic agents, and translocation of the GLUT4 glucose transporter in insulin-stimulated adipocytes and skeletal muscle(25, 26, 27, 28, 29, 30, 31) . These data have been interpreted as demonstrating a role for the p85/p110 PI 3`-kinase in these processes. However, a number of PI kinase isoforms are sensitive to wortmannin, including both PI 3-kinases and PI 4-kinases(16, 24, 32) . Despite questions as to the specificity of these findings, there is a growing body of evidence suggesting a role for 3-phosphoinositides in intracellular trafficking.

In this study, we examined a number of endocytic and biosynthetic trafficking pathways in CHO cells using wortmannin, which irreversibly inhibits several PI kinase isoforms. Treatment of cells with 100 nM wortmannin causes a 50% reduction of cell-surface transferrin receptors due to an increase in the internalization rate and a decrease in the recycling rate. Consistent with these changes, the morphology of the recycling compartment is altered by wortmannin, and movement of transferrin into and out of the recycling compartment is slowed. We also find that wortmannin slows the delivery of endocytosed Semliki Forest virus to its lysosomal site of degradation. However, we were unable to detect any changes in the transit of newly synthesized viral glycoproteins through the Golgi apparatus and to the plasma membrane, and we detected alterations in the sorting of newly synthesized lysosomal enzymes only at micromolar concentrations of wortmannin. Our data demonstrate the presence of wortmannin-sensitive enzymes that regulate receptor-mediated endocytosis and recycling. These enzymes are pharmacologically distinct from those involved in the sorting of newly synthesized lysosomal proteases.


EXPERIMENTAL PROCEDURES

CHO Cell Lines

TRVb-1 cells are derived from CHO-WTB cells and express 10^5 human transferrin receptors/cell(33) . CHO/IR cells are derived from CHO-K1 cells and express 10^6 wild-type human insulin receptors/cell (exon 11-minus isoform(34, 35) ).

Inhibition of PI 3`-Kinase by Wortmannin

Wortmannin (Sigma) was stored in dimethyl sulfoxide at -70 °C and diluted into protein-free medium just prior to use. Inhibition of PI 3`-kinase in intact cells was measured by incubating CHO/IR cells with the indicated concentrations of wortmannin or dimethyl sulfoxide carrier (0.1%, v/v) for 30 min at 37 °C. After an additional incubation in the absence or presence of 100 nM insulin, the cells were lysed, and PI 3`-kinase activity in anti-p85 immunoprecipitates was determined as described previously(7) .

Transferrin Uptake and Recycling

TRVb-1 cells cultured in 6-well dishes were incubated in the absence or presence of wortmannin (100 nM unless otherwise indicated, in a final concentration of 0.1% dimethyl sulfoxide) for 45 min at 37 °C; control experiments showed that 0.1% dimethyl sulfoxide does not affect trafficking parameters in TRVb-1 cells. Transferrin endocytosis was measured, and endocytic rate constants were calculated using the In/Sur method as described previously(33, 36) . In experiments examining both internalization and surface binding at 37 °C, parallel sets of untreated or wortmannin-treated cells were incubated with I-labeled transferrin for 0-10 min and then washed with neutral buffer, to determine surface-bound radioactivity, or with acidic buffer, to determine intracellular radioactivity. Uptake of Fe-labeled transferrin was measured by incubating untreated or wortmannin-treated cells (100 nM; 45 min) in the presence of 10 µg/ml Fe-labeled transferrin as described(33) .

To measure recycling, TRVb-1 cells were incubated with I-labeled transferrin for 2 h at 37 °C, followed by an additional 45 min with I-labeled transferrin in the absence or presence of 100 nM wortmannin. The cells were washed with 50 mM MES (pH 5.0) and 150 mM NaCl to remove surface-bound transferrin and incubated in 600 µg/ml unlabeled transferrin and 100 µg/ml desferoxamine in the continued absence or presence of wortmannin. At various times, the medium and one wash were collected, and the cells were solubilized to determine recycled and cell-associated radioactivity.

Insulin Endocytosis

Cells were pretreated with 100 nM wortmannin or carrier (0.1% (v/v) dimethyl sulfoxide) for 30 min at 37 °C. Insulin internalization was measured, and internalization rate constants were calculated as described previously (37) .

Analysis of Transferrin Trafficking by Immunofluorescence

In pulse-chase experiments, TRVb-1 cells grown on coverslips were incubated in 100 nM wortmannin or carrier for 30 min at 37 °C. Cells were incubated with Cy3-transferrin (10 µg/ml) for 3 min, washed, and chased in the continued absence or presence of wortmannin. At various times, the cells were washed and fixed in 3.7% formaldehyde as described (38) and examined using a Bio-Rad MRC 600 laser scanning confocal microscope with Nikon times60 NA 1.4 planapo optics. Serial images were collected at 0.6-µm steps over the depth of the cells and projected using the maximum pixel method and were printed using a Sony Mavigraph color video printer. In the sorting experiments, cells were incubated in Cy3-transferrin for 15 min, washed, and then chased with medium containing FITC-transferrin (10 µg/ml) in the absence or presence of 100 nM wortmannin. Cells were washed three times after the chase period, fixed in 3.7% formaldehyde, and examined using a Zeiss Axiovert microscope at times63 or times100. Images were photographed directly from the microscope using identical exposure times.

Uptake and Degradation of S-Labeled Semliki Forest Virus

[S]Methionine-labeled Semliki Forest virus was prepared and purified as described(39) . CHO/IR or TRVb-1 cells grown in 35-mm plates were pretreated in the absence or presence of 100 nM wortmannin for 30 min at 37 °C. The cells were then incubated for 1.5 h at 4 °C with S-labeled Semliki Forest virus in the continued absence or presence of wortmannin. After a rinse in cold medium to remove unbound virus, internalization and degradation of surface-bound SFV were determined as described(40) .

Measurement of Endosomal Acidification with Conformation-specific Antibodies

The effect of wortmannin on endosomal acidification was determined by following the acid-induced conformational change in the Semliki Forest virus E1 spike protein as described previously(41) . Briefly, TRVb-1 cells were incubated for 30 min at 37 °C in the presence of 100 nM wortmannin or carrier and incubated with S-labeled SFV at 4 °C as described above. The cells were warmed rapidly to 37 °C to initiate endocytosis and lysed at various times. Lysates were incubated with a rabbit polyclonal antibody against the SFV spike protein or with monoclonal antibody E1a-1, which specifically recognizes the SFV E1 glycoprotein only after it has undergone an acid-dependent conformational change(40) . Immunoprecipitated proteins were analyzed as described(40) .

Transit of Newly Synthesized Vesicular Stomatitis Virus Glycoproteins

Biosynthetic trafficking of the vesicular stomatitis virus spike protein (VSV-G) was analyzed as described previously(42) . Briefly, CHO cells cultured in 35-mm dishes were infected with vesicular stomatitis virus (20 plaque-forming units/cell). The cells were treated without or with 100 nM wortmannin for 30 min at 37 °C in methionine-free medium, labeled with [S]methionine (50 µCi/well) for 5 min, and chased for various periods of time in medium containing 0.15 mg/ml methionine. Total radiolabeled VSV-G was precipitated with trichloroacetic acid (10% final concentration) and analyzed by SDS-polyacrylamide gel electrophoresis(43) . Plasma membrane VSV-G was labeled by biotinylation with N-hydroxysuccinimidobiotin (Pierce), collected on streptavidin-agarose beads, and analyzed as described(44) . Total and plasma membrane S-labeled VSV-G was quantitated using a PhosphorImager (Molecular Dynamics, Inc.).

Processing of Newly Synthesized Semliki Forest Virus Spike Proteins

Processing of the SFV E1 and E2 spike proteins in wortmannin-treated cells was analyzed as described previously(40) . Briefly, CHO cells grown in 35-mm dishes were infected with SFV (100 plaque-forming units/cell). Cells were incubated for 30 min in the absence or presence of 100 nM wortmannin in methionine-free medium, labeled with [S]methionine (50 µCi/plate) for 30 min, and chased in medium containing excess methionine in the continued absence or presence of wortmannin. At various times, S-labeled spike proteins were immunoprecipitated from solubilized cells and analyzed as described(40) . Viral budding was determined by immunoprecipitation of S-labeled proteins from solubilized aliquots of the medium.

Secretion of Cathepsin D

Analysis of cathepsin D synthesis was performed as described by Richo and Conner(45) . TRVb-1 or CHO/IR cells, grown in 35-mm dishes, were incubated for 30 min in wortmannin as indicated in methionine-free medium, labeled with [S]methionine for 30 min, and chased in medium containing excess methionine in the continued absence or presence of wortmannin. At various times, the medium was removed, SDS was added (0.4% final concentration), and the samples were boiled. The cells were solubilized in 0.5 ml of boiling lysis buffer as described(45) . Both the medium and cells were carboxymethylated by a 1-h incubation in 50 mM iodoacetamide. S-Labeled cathepsin D was immunoprecipitated with anti-cathepsin D antibody (a generous gift of Dr. Gregory Conner, University of Miami School of Medicine) and protein A-Sepharose (Pharmacia Biotech Inc.), eluted, and analyzed by reducing SDS-polyacrylamide gel electrophoresis (10% resolving gel).


RESULTS

Inhibition of PI 3`-Kinase by Wortmannin

We determined the concentration of wortmannin required to inhibit the p85/p110 PI 3`-kinase in intact cells. A 30-min incubation with 100 nM wortmannin reduced both basal and insulin-stimulated p85/p110 activity by 70-80% (data not shown). Basal PI 3`-kinase activity showed half-maximal inhibition at 30 nM wortmannin and maximal inhibition at 100 nM, with no additional decrease in activity at 1 µM wortmannin (Fig. 1). Subsequent experiments used 100 nM wortmannin unless otherwise indicated.


Figure 1: Inhibition of PI 3`-kinase by wortmannin. CHO cells were incubated in the presence of 0.1% dimethyl sulfoxide or dimethyl sulfoxide containing the indicated concentrations of wortmannin. The cells were lysed, and PI 3`-kinase activity in anti-p85 immunoprecipitates was assayed. Data are the means ± S.E. of triplicates and are representative of three separate experiments.



Effect of Wortmannin on the Endocytic Pathway

Previous studies suggest a role for wortmannin-sensitive enzymes in the endocytic pathway(23) . We examined the effect of wortmannin on transferrin receptor trafficking using TRVb-1 cells, which overexpress the human transferrin receptor. Treatment of TRVb-1 cells with wortmannin resulted in a depletion of cell-surface transferrin receptors (Fig. 2A). Half-maximal depletion was observed at 30 nM wortmannin, and a maximal 40-50% depletion was achieved at 100 nM wortmannin. No further decrease in cell-surface receptors was observed at concentrations as high as 1 µM wortmannin (data not shown). The effect of wortmannin on cell-surface transferrin receptors corresponded with the dose response for inhibition of the p85/p110 PI 3`-kinase.


Figure 2: Transferrin endocytosis and recycling. A, cells were treated with the indicated concentrations of wortmannin for 45 min at 37 °C. The cells were chilled, and surface I-labeled transferrin binding was determined. Data are the means ± S.E. of triplicates and are representative of two separate experiments. B, TRVb-1 cells were incubated in the absence or presence of 100 nM wortmannin for 45 min at 37 °C. The cells were incubated for various times with I-labeled transferrin (3 µg/ml), rapidly chilled, and washed with either neutral or acidic buffer for determination of cell-associated or internalized radioactivity, respectively. Surface-bound radioactivity was calculated as the difference between cell-associated and internalized transferrin. Data are the means ± S.E. of triplicates and are representative of five separate experiments. C, shown is an In/Sur plot of I-labeled transferrin uptake in control and wortmannin-treated cells. Data are the means ± S.E. of triplicates and are representative of nine separate experiments. D, cells were incubated in the presence of I-labeled transferrin for 2 h at 37 °C, followed by an additional 45 min in the presence of 100 nM wortmannin or carrier. After a mild acid wash to remove surface-bound ligand, the cells were incubated in medium containing 100 µg/ml desferoxamine and 600 µg/ml unlabeled transferrin in the continued absence or presence of wortmannin. Release of I-labeled transferrin into the medium was calculated as a percentage of total intracellular transferrin at 0 min. Data are the means ± S.E. of triplicates and are representative of seven separate experiments.



We then measured the uptake of I-labeled transferrin during a 10-min incubation at 37 °C in TRVb-1 cells. Pretreatment with wortmannin for 30 min decreased the accumulation of surface-bound and intracellular transferrin (Fig. 2B). The change in cell-surface transferrin binding reflected a redistribution of cell-surface transferrin receptors into an intracellular compartment, as total cellular transferrin binding was unaffected by wortmannin (data not shown). To determine the mechanism for this redistribution, we measured the rates of internalization and recycling in wortmannin-treated cells. The internalization rate constant for I-labeled transferrin was calculated by the In/Sur method(36) ; a representative experiment is shown in Fig. 2C. In data pooled from nine experiments, the rate constant for transferrin receptor endocytosis was increased 55% by wortmannin (Table 1). Similarly, the rate of Fe uptake was increased 60% by treatment of cells with wortmannin (Table 1). Although the calculated rate constants differed using the two methods, in both cases, treatment of cells with 100 nM wortmannin caused a similar increase in the internalization rate (Table 1). Although there was a decrease in the absolute amount of internalized I-labeled transferrin in wortmannin-treated cells (Fig. 2B), the internalization rate constants are calculated on a per receptor basis and are in fact increased by wortmannin.



In addition to the effects on internalization, the rate of transferrin recycling was reduced by treatment of cells with wortmannin. Cells were preloaded with I-labeled transferrin in the absence of wortmannin (to prevent any differences in the concentration of intracellular ligand) and then incubated in 100 µM desferoxamine in the absence or presence of wortmannin (a representative experiment is shown in Fig. 2D). In data pooled from seven experiments, we observed a 33% decrease in the rate of I-labeled transferrin efflux from the wortmannin-treated cells (Table 1).

The steady-state distribution of transferrin receptors between the interior and surface of cells is determined by both the rates of endocytosis (k(e)) and recycling (k(r)). Changes in either parameter will be reflected in a new steady-state distribution. The increase in k(e) and the decrease in k(r) observed in wortmannin-treated cells predict a redistribution of transferrin receptors from the cell surface to the cell interior, resulting in a decrease in surface binding. The magnitude of the predicted change in surface binding, based on the ratio of the changes in k(e) and k(r), was similar to the observed decrease in cell-surface I-labeled transferrin binding (42% as opposed to 45%) (Table 1).

We also measured the internalization of I-labeled insulin in CHO/IR cells, which overexpress the human insulin receptor. Unlike transferrin receptors, which internalize constitutively, insulin receptors enter coated pits in a ligand-stimulated manner(46, 47) . Moreover, changes in the insulin receptor membrane-spanning domain that increase the rate of receptor lateral diffusion on the cell surface increase the rate of receptor endocytosis(48) , suggesting that events prior to entry into coated pits are rate-limiting for insulin receptor endocytosis. We found that the rate constant for I-labeled insulin uptake in CHO/IR cells was unaffected by wortmannin (k(e) = 0.116 ± 0.006 versus 0.125 ± 0.01 in the absence and presence of wortmannin) (data not shown). Thus, the ligand-stimulated events that precede entry of insulin receptors into coated pits appear to be independent of wortmannin-sensitive enzymes.

Morphology of the Recycling Compartment

We used Cy3-transferrin to visualize the intracellular itinerary of internalized transferrin receptors. In control cells incubated with Cy3-transferrin for 3 min followed by a 2-min chase in the absence of transferrin, receptor-bound transferrin is present in early endosomes and sorting endosomes (Fig. 3A), compartments that have been previously shown to colabel with endocytosed low density lipoprotein(38) . After an additional 10 min of chase, the receptor-bound transferrin is sorted away from the degradation pathway to the pericentriolar recycling compartment, located near the Golgi apparatus (Fig. 3B). The receptor and its ligand then return to the plasma membrane for another round of internalization. Exit from the pericentriolar compartment is the rate-limiting step in the recycling of transferrin and results in a concentration of the transferrin receptor in the pericentriolar region of the cell (Fig. 3B)(38) .


Figure 3: Uptake of Cy3-transferrin in wortmannin-treated cells. TRVb-1 cells were incubated for 30 min in the presence of 100 nM wortmannin or carrier. After the addition of Cy3-transferrin (10 µg/ml) for 3 min, the cells were washed and chased for various times in the continued absence (A and B) or presence (C and D) of wortmannin. A and C, 2 min of chase; B and D, 12 min of chase. Serial images were collected at 0.6-µm steps over the depth of the cells and were projected using the maximum pixel method.



In contrast, pretreatment of cells with wortmannin delayed the sorting of internalized transferrin to the recycling compartment. When wortmannin-treated cells were labeled with Cy3-transferrin and chased in wortmannin for 2 min, we saw an accumulation of ligand in numerous peripheral punctate structures similar to those seen in control cells (Fig. 3C). The intensity of labeling was decreased in wortmannin-treated cells relative to control cells, reflecting the decrease in cell-surface transferrin receptors caused by preincubation with wortmannin (Fig. 2B). After 12 min of chase, the distribution of labeled transferrin in wortmannin-treated cells was significantly different than in control cells, with a persistence of label in peripheral punctate structures (Fig. 3D). After 16 min of chase, pericentriolar concentration could be seen in some wortmannin-treated cells (data not shown). However, the labeled structures in these cells were more vesiculated and less uniform in appearance that those in control cells (data not shown; but see Fig. 4, A and B).


Figure 4: Trafficking of Cy3-transferrin in wortmannin-treated cells. TRVb-1 cells were incubated with Cy3-transferrin for 15 min at 37 °C and then chased for 15 min (A-D) or 45 min (E-H) in FITC-transferrin in the absence or presence of 100 nM wortmannin. A and C, B and D, E and G, and F and H show the same field of cells viewed with either Cy3- or FITC-specific filters, respectively. Control cells are shown in A, C, E, and G; cells chased in wortmannin are shown in B, D, F, and H.



These data suggest that wortmannin reduces the rate of delivery of internalized transferrin from endosomes to the recycling compartment. Alternatively, the altered morphology of the labeled compartment in wortmannin-treated cells could reflect a change in the fidelity of sorting, with delivery of internalized transferrin to a different compartment. To differentiate these possibilities, we examined the degree to which transferrin internalized prior to wortmannin treatment mixed with transferrin internalized in the presence of wortmannin. Cells were preincubated to equilibrium by a 45-min incubation with Cy3-transferrin in the absence of wortmannin; under these conditions, label accumulates in the pericentriolar recycling compartment. The cells were then washed and chased in medium containing FITC-transferrin in the absence or presence of 100 nM wortmannin. During this incubation, Cy3-transferrin effluxes from the cells, whereas FITC-transferrin accumulates.

In untreated cells labeled with Cy3-transferrin and then chased with FITC-transferrin for 15 min, residual Cy3 labeling of the recycling compartment was easily observable (Fig. 4A). Moreover, FITC-transferrin could be seen to accumulate in the same intracellular compartment that contains Cy3-transferrin (Fig. 4C). In cells chased with FITC-transferrin in the presence of wortmannin for 15 min, the residual Cy3 labeling of the recycling compartment is much brighter than in control cells (Fig. 4B), indicating that wortmannin slowed the recycling of transferrin receptors back to the cell surface. Moreover, the vesiculation of the pericentriolar compartment in wortmannin-treated cells is evident (Fig. 4B). However, the altered compartment is still clearly labeled with FITC-transferrin (Fig. 4D), indicating that this compartment is in communication with early endosomal structures containing newly internalized transferrin.

The wortmannin-induced slowing of efflux from the recycling compartment is even more striking after a 45-min chase. In control cells chased for 45 min, Cy3-transferrin in the pericentriolar structures has been substantially washed out (Fig. 4E), replaced by FITC-transferrin that entered during the chase (Fig. 4G). In contrast, the punctate pericentriolar structures in wortmannin-treated cells are still brightly labeled with Cy3-transferrin after 45 min (Fig. 4F). Again, Cy3-transferrin colocalizes with newly internalized FITC-transferrin (Fig. 4H), suggesting that the punctate pericentriolar structures in wortmannin-treated cells are in communication with early endosomal structures. The increased labeling of the recycling compartment during the FITC-transferrin chase in wortmannin-treated cells (Fig. 4, compare C with D and G with H) reflects the wortmannin-induced redistribution of transferrin-receptor complexes into the cell interior (Fig. 2A). Taken together, the data in Fig. 3and Fig. 4show that wortmannin has a pronounced inhibitory effect on both entry into and efflux from the recycling compartment.

Effects of Wortmannin on Lysosomal Delivery and Endosomal Acidification

The endocytic system internalizes both ligands and receptors by a common pathway, subsequently sorting receptors for recycling and ligands for lysosomal degradation. To determine whether wortmannin affects the sorting of ligands into a degradative pathway, we measured the degradation of endocytosed S-labeled SFV, which is sorted from endosomes to the lysosome(49) . In control cells, we observed a characteristic 10-15-min lag period before the appearance of viral degradation products in the medium, which reached a maximum at 90 min (Fig. 5). In contrast, the time lag before the detection of degraded SFV in the medium was longer (20-30 min) in wortmannin-treated cells, and degraded SFV in the medium of wortmannin-treated cells was half that of control cells by 90 min. The differences in the rates of SFV degradation could not be explained by differences in the rates of internalization of surface-bound SFV, which were not affected by wortmannin (data not shown).


Figure 5: Degradation of endocytosed Semliki Forest virus. CHO cells were pretreated with 100 nM wortmannin or carrier and then incubated with S-labeled Semliki Forest virus for 1.5 h at 4 °C. The cells were washed and warmed to 37 °C in the continued absence or presence of wortmannin. At various times, aliquots of the medium were removed to determine the release of trichloroacetic acid-soluble radioactivity. Trichloroacetic acid-soluble radioactivity is expressed as a percentage of initial cell-associated radioactivity.



Although these data suggest that wortmannin had significant effects on the kinetics of late endosomal sorting, the altered kinetics of SFV degradation could be due to effects on the acidification of the endosomal lumen. We therefore examined the endocytic uptake of S-labeled SFV using a conformation-specific antibody to the SFV E1 spike protein. The E1 spike protein undergoes a conformational change when exposed to the acidic conditions of the early endosome (pH 6.2 or lower), exposing an epitope that is recognized by monoclonal antibody E1a-1(40) .

Untreated (Fig. 6A) or wortmannin-treated (Fig. 6B) cells were allowed to bind S-labeled SFV at 4 °C and then warmed rapidly to 37 °C. At various times, the cells were lysed, and proteins were precipitated with either anti-spike antibody or conformation-specific antibody E1a-1. No difference in the total amount of cell-associated virus was detected in control versus wortmannin-treated cells (Fig. 6, A and B, lanes a). In both treated and untreated cells, a decrease in cell-associated virus due to lysosomal degradation was apparent by 15-30 min (Fig. 6, A and B, lanes d and e). Similarly, in both untreated and wortmannin-treated cells, the E1 spike protein was first recognized by antibody E1a-1 after 5 min at 37 °C (Fig. 6, A and B, lanes j), with levels of E1a-1-precipitable protein reaching maximal levels by 15 min (lanes l). In control experiments, treatment of cells with monensin completely blocked the conversion of E1 to the acidic conformation (Fig. 6, A and B, lanes o), whereas brief treatment of bound virus with acidic buffer (pH 5.5) caused maximal conversion of the E1 protein to its acidic conformation (lanes p). We conclude that endosomal acidification is not grossly affected by wortmannin.


Figure 6: Effect of wortmannin on endosomal acidification. TRVb-1 cells pretreated with carrier (A) or 100 nM wortmannin (B) were allowed to bind S-labeled SFV on ice for 90 min. After washes to remove unbound virus, the cells were warmed to 37 °C in the continued absence or presence of wortmannin. At various times, the cells were lysed, and S-labeled viral proteins were immunoprecipitated with anti-spike antibody (A and B, lanes a-h) or antibody E1a-1 (lanes i-p), which recognizes the E1 spike protein after it has undergone an acid-dependent conformational change. Lanes g and o show immunoprecipitates from incubations that included monensin (10 µM) to block acidification. Lanes h and p show cells treated with pH 5.5 buffer for 1 min prior to lysis.



Effect of Wortmannin on Biosynthetic Trafficking

We examined the transit and processing of VSV-G and the SFV E2 glycoprotein to determine the potential effects of wortmannin on biosynthetic vesicular trafficking. To measure the net rate of delivery of newly synthesized membrane glycoprotein to the plasma membrane in the absence or presence of wortmannin, we infected CHO cells with vesicular stomatitis virus, pulse-labeled the cells with [S]methionine, and specifically labeled plasma membrane VSV-G by a cell-surface biotinylation protocol at 4 °C. The kinetics of VSV-G arrival at the plasma membrane was consistent with previous studies (50) and was unaffected by 100 nM wortmannin (data not shown). We also examined the processing of the SFV E1 and E2 spike proteins, which occurs in a post-Golgi compartment(40, 51) . SFV-infected cells were incubated in the absence or presence of 100 nM wortmannin and pulse-labeled with [S]methionine. Processing of the SFV spike proteins was then analyzed by immunoprecipitation and SDS-polyacrylamide gel electrophoresis. Wortmannin had no effect on the cleavage of the E2 glycoprotein from its 62-kDa precursor form to its mature form (data not shown). Secretion of assembled virions was also unaffected by wortmannin (data not shown). Taken together, the experiments with VSV and SFV indicate that wortmannin does not affect transit of newly synthesized glycoproteins from the endoplasmic reticulum, through the Golgi apparatus, and to the plasma membrane.

Effect of Wortmannin on Lysosomal Sorting

Lysosomal hydrolases are sorted to the lysosome in CHO cells by virtue of the binding of mannose 6-phosphate residues to the mannose 6-phosphate receptor in the Golgi apparatus(52) . A small proportion of lysosomal hydrolases are also secreted, and this alternative pathway is augmented during transformation of a number of cell types(53) . In yeast, mutation of VPS-34 causes the missorting of vacuolar hydrolases to the secretory pathway(20) . Moreover, two recent studies have suggested that wortmannin diverts newly synthesized cathepsin D into the secretory pathway(54, 55) . To determine if treatment of CHO cells with wortmannin caused a similar perturbation of lysosomal enzyme sorting, we measured the secretion of cathepsin D into the medium of cells treated with 100 nM wortmannin. Fig. 7A shows total intracellular cathepsin D and secreted cathepsin D from control or wortmannin-treated cells; the two gels were intentionally overexposed for identical lengths of time to permit visualization of secreted cathepsin D. 100 nM wortmannin had no effect on either the synthesis or stability of intracellular cathepsin D (Fig. 7A, upper panel), and secretion of cathepsin D was extremely low in both untreated and wortmannin-treated cells (lower panel). In five separate experiments, we detected no significant increases in cathepsin D secretion in cells treated with 100 nM wortmannin.


Figure 7: Secretion of cathepsin D in wortmannin-treated cells. A, TRVb-1 cells were incubated in 100 nM wortmannin or carrier for 30 min in methionine-free medium plus an additional 30 min with [S]methionine, followed by a chase in the continued absence or presence of wortmannin. At various times, the medium was harvested, the cells were lysed, and intracellular or secreted S-labeled cathepsin D was immunoprecipitated and analyzed by SDS-polyacrylamide gel electrophoresis. B, cells were incubated in the absence or presence of 2 µM wortmannin or 50 µM chloroquine for 30 min and then processed as described above. The fluorographic exposure for B was one-third that used in A, which was intentionally overexposed to visualize secreted cathepsin D.



In contrast to the data obtained with 100 nM wortmannin, we saw a significant effect on the secretion of cathepsin D after treatment of cells with 2 µM wortmannin. This concentration of drug is 20-fold higher than that required for maximal effects on p85/p110 PI 3`-kinase activity or transferrin receptor redistribution. Fig. 7B shows identical exposures of intracellular and secreted cathepsin D from control cells, cells treated with 2 µM wortmannin, or cells treated with 50 µM chloroquine. Treatment of cells with 2 µM wortmannin had no significant effect on the synthesis or stability of intracellular cathepsin D, whereas treatment of cells with chloroquine increased the intracellular half-life of newly synthesized cathepsin D, presumably by inhibiting lysosomal degradation (Fig. 7B, upper panel). Notably, both 2 µM wortmannin and 50 µM chloroquine had pronounced effects on the secretion of newly synthesized cathepsin D. Secreted cathepsin D was undetectable in control cells (Fig. 7B, lower panel) using a fluorographic exposure time one-third of that used in Fig. 7A. In contrast, secreted cathepsin D was easily seen after 3 h in cells treated with 2 µM wortmannin (Fig. 7B, lower panel). 2 µM wortmannin induced a level of cathepsin D secretion similar to that seen in cells treated with chloroquine, a drug that is known to divert lysosomal enzymes into the secretory pathway(56) .

Morphology of the Recycling Compartment in the Presence of Micromolar Concentrations of Wortmannin

These data suggest that high doses of wortmannin induce changes in cellular physiology quite different than those observed at 100 nM wortmannin. We therefore examined the morphology of the recycling compartment loaded with Cy3-transferrin for 45 min in the presence of 1 µM wortmannin (Fig. 8). A high dose of wortmannin induced the formation of a tubular network that extended throughout the cytoplasm. Moreover, there was a much more marked dispersal of the pericentriolar transferrin-labeled compartment and an increase in large punctate structures in the cell periphery. Thus, micromolar concentrations of wortmannin induce changes distinct from those observed at concentrations that maximally inhibit the p85/p110 PI 3`-kinase.


Figure 8: Morphology of the sorting compartment in cells treated with micromolar concentrations of wortmannin. TRVb-1 cells were incubated for 45 min in the presence of 5 µg/ml Cy3-transferrin, followed by an additional 45 min in the presence of Cy3-transferrin and 1 µM wortmannin. A and B represent two different optical sections from the same field.




DISCUSSION

Studies from several different laboratories suggest that PI 3`-kinase plays a role in endocytic or other trafficking events in mammalian cells. In this paper, we examined trafficking events in CHO cells treated with 100 nM wortmannin(27, 57, 58) , which maximally inhibits the p85/p110 PI 3`-kinase in these cells. We find that 100 nM wortmannin causes a significant redistribution of the transferrin receptor due to changes in both the endocytic and recycling rate constants. Moreover, wortmannin induces a vesicularization of the recycling compartment labeled with fluorescent transferrin and reduces the rate at which transferrin enters and exits this compartment. Transferrin receptor trafficking and p85/p110 PI 3`-kinase activity show similar sensitivities to wortmannin, consistent with the involvement of p85/p110 or a related enzyme in the regulation of endocytosis and recycling.

The effects of 100 nM wortmannin appear to be specific for the endocytic system, as we could not detect any changes in biosynthetic trafficking of SFV or VSV spike proteins. We did detect an enhancement of the secretion of cathepsin D, a phenotype similar to that observed in yeast containing mutant VPS-34 alleles, but only at micromolar concentrations of wortmannin. These data are consistent with those of Balch and co-workers(54) , who reported missorting of cathepsin D at 1-2 µM wortmannin in CHO and normal rat kidney cells, but differ from those of Davidson(55) , who observed effects on cathepsin D sorting at 100 nM wortmannin in K-532 cells. Presumably, the discordance reflects different sensitivities of the lysosomal enzyme-sorting apparatus in different cell types. However, our CHO cell data strongly suggest that the wortmannin-sensitive enzymes involved in lysosomal sorting are distinct from those involved in transferrin recycling and are unlikely to be the p85/p110 PI 3`-kinase. Furthermore, treatment of cells with 1 µM wortmannin causes an extensive tubulation and vesiculation of the transferrin-labeled compartment, which is barely visible at 100 nM wortmannin. The disruption of transferrin receptor cycling in CHO cells by 100 nM wortmannin therefore defines a sorting event(s) that is pharmacologically distinct from the wortmannin-sensitive steps in lysosomal enzyme delivery.

The identity of the wortmannin-sensitive enzymes involved in transferrin endocytosis and recycling is not clear, as the specificity of wortmannin with regard to PI 3`-kinase is extremely problematic. Wortmannin was initially described as an inhibitor of the myosin light chain kinase, but it irreversibly inhibits PI 3`-kinase at 100-fold lower concentrations(26, 27, 57, 58) . Both alpha- and beta- isoforms of the p110 PI 3`-kinase are half-maximally inhibited by low nanomolar concentrations of wortmannin, as is the recently cloned PI-specific PI 3`-kinase ; the sensitivity of the beta-stimulated PI 3`-kinase is not yet clear(16, 18, 59) . In addition, a PI 4-kinase important in the regulation of intracellular PI(4)P and PI(4,5)P(2) levels is half-maximally inhibited by 100 nM wortmannin and completely inhibited by 1 µM wortmannin(32) . This finding is particularly important; PI(4,5)P(2) has been implicated in the regulation of AP-2 adaptin complexes and cytoskeletal components such as profillin and plays a role in regulated secretion (60, 61, 62) . Moreover, PIP(2) has been shown to bind to pleckstrin homology domains, suggesting that disruption of PIP(2) synthesis could affect numerous cellular functions (63) . The existence of multiple wortmannin-inhibited enzymes, which are regulated by different mechanisms and may exist in distinct intracellular locations, compromises the use of wortmannin as a putatively specific inhibitor of PI 3`-kinase. Studies currently in progress, involving the microinjection of inhibitory anti-p110 antibodies into TRVb-1 cells, will address the question of whether the wortmannin-sensitive enzyme involved in transferrin trafficking is the p85/p110 PI 3`-kinase.

The kinetic analysis of transferrin receptor trafficking and Semliki Forest virus degradation in wortmannin-treated cells demonstrates that three distinct steps in endocytic trafficking are affected by the drug. First, we see an increase in the rates of I-labeled transferrin endocytosis and Fe accumulation, both of which measure the rate of constitutive coated pit-mediated internalization. It is therefore possible that a wortmannin-sensitive enzyme is important in regulating the early rate-limiting steps governing coated pits. We did not see changes in the rates of internalization of either I-labeled insulin or surface-bound S-labeled SFV. However, both insulin and SFV initially bind to receptors located in the microvillous regions of the cell membrane and then move to coated pits(47, 49) . Furthermore, the rate of insulin receptor endocytosis appears to be limited by the rate of receptor diffusion through the plasma membrane (48) and therefore is probably not a reflection of the absolute rate of coated pit endocytosis.

A second site of wortmannin action may be the sorting endosome. In CHO cells, recycled ligands are sorted from material destined for degradation by an iterative fractionation process in which the sorting endosome matures into a late endosome(38) . Consequently, if wortmannin affects the maturation of the sorting endosome, then both transport of the recycling membrane to the pericentriolar recycling compartment and delivery of material to lysosomes could be affected. Consistent with this possibility, wortmannin slows the movement of internalized receptor-bound transferrin from endosomes to the pericentriolar recycling compartment as well as the degradation of internalized SFV, which requires delivery to the lysosome. These changes do not appear to be due to defects in luminal acidification, which is known to affect intracellular trafficking of the transferrin receptor(64, 65) , as the acid-dependent conformational changes in the SFV E1 spike protein are normal in wortmannin-treated cells. Although our data could be explained by a common wortmannin-sensitive step in the sorting compartment, we cannot rule out the possibility of independent wortmannin-sensitive steps involved in transit of ligands between the sorting endosome and the recycling compartment or the lysosome. These steps could involve Rab5 or another Rab isoform, as has been recently suggested by Li et al.(66) .

A third potential site of action is the recycling compartment, defined as the pericentriolar structure that is labeled by fluorescent transferrin, but not by ligands like low density lipoprotein that are destined for lysosomal degradation(38) . Transport from the pericentriolar recycling compartment is the rate-limiting step in transferrin recycling(38) . The morphology of the recycling compartment is significantly altered by 100 nM wortmannin, and efflux of transferrin out of the compartment is slowed in wortmannin-treated cells. Although the mechanism by which wortmannin affects the recycling compartment is not yet clear, there is precedent for the regulation of transit from the recycling compartment. Thus, transferrin receptor recycling from the compartment to the plasma membrane is slowed by either alkalinization of the lumen or oligomerization of transferrin receptors in the presence of multivalent transferrin(64, 67) .

The redistribution of transferrin receptors caused by wortmannin is similar to that seen in a mutant liver line (Trf1) that expresses only State 1 receptors(68, 69) , defined by Weigel (68) as receptors resistant to down-regulation by metabolic and cytoskeletal inhibitors. However, residual surface receptors in Trf1 cells show unchanged endocytosis and accelerated recycling(69) . Receptor redistributions in wortmannin-treated cells therefore involve different mechanisms than those operative in Trf1 cells.

For the most part, the studies presented here examine trafficking under basal conditions of PI 3`-kinase activity. Some activation of PI 3`-kinase may occur during insulin-stimulated endocytosis in CHO/IR cells, although the studies were performed at insulin concentrations well below the half-maximal concentrations required for activation of PI 3`-kinase(70, 71) . Moreover, we have previously shown that mutant insulin receptors that do not activate PI 3`-kinase still undergo normal ligand-stimulated endocytosis(72, 73) . Siddle and co-workers (74) recently reported that wortmannin blocks insulin-stimulated up-regulation of the transferrin receptor in 3T3-L1 cells, and Joly et al.(23) have shown that treatment of cells with wortmannin or mutation of PI 3`-kinase-binding sites alters the post-endocytic routing of internalized platelet-derived growth factor receptors. Both of these studies examined cells under conditions of mitogen-induced PI 3`-kinase activation and may not be strictly comparable to the studies presented here.

In summary, we have evaluated the effects of wortmannin on vesicular trafficking in CHO cells. We find that concentrations of wortmannin that maximally inhibit the p85/p110 PI 3`-kinase have pronounced effects on three distinct steps in the endocytic cycle: internalization, transit from early endosomes to the recycling and degradative compartments, and transit from the recycling compartment back to the cell surface. A substantial change in the morphology of the sorting compartment is also seen under these conditions. However, we find no effects on the biosynthetic trafficking of viral glycoproteins or lysosomal enzymes at these concentrations. In contrast, wortmannin-induced secretion of cathepsin D was observed at significantly higher doses of wortmannin. We have therefore identified two thresholds of wortmannin-sensitive events in vesicular sorting, suggesting that the effects on endocytic and lysosomal trafficking are mechanistically distinct.


FOOTNOTES

*
This work was supported in part by National Institutes of Health Grant DK-44541 and by grants from the Alexander and Alexandrine Sinsheimer Fund and the Council for Tobacco Research (to J. M. B.), American Cancer Society Grant ACS-CB8 (to T. E. M), and National Institutes of Health Grant GM-52929 (to M. C. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Contributed equally to this work.

Recipient of a fellowship from the Howard Hughes Medical Foundation.

**
To whom correspondence should be addressed: Dept. of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461. Tel.: 718-430-2153; Fax: 718-430-8922.

(^1)
The abbreviations used are: PI, phosphatidylinositol; CHO, Chinese hamster ovary; MES, 4-morpholineethanesulfonic acid; FITC, fluorescein isothiocyanate; SFV, Semliki Forest virus; VSV-G, vesicular stomatitis virus glycoprotein.


ACKNOWLEDGEMENTS

We thank Dr. Gregory Conner for the generous gift of anti-cathepsin D antibodies and Matthew Klimjack for expert technical assistance. We also thank Dr. Conner and Drs. George Orr and Dennis Shields for extremely helpful discussions and suggestions and Michael Cammer (Analytical Imaging Facility, Albert Einstein College of Medicine).


REFERENCES

  1. Otsu, M., Hiles, I., Gout, I., Fry, M. J., Ruiz-Larrea, F., Panayotou, G., Thompson, A., Dhand, R., Hsuan, J., Totty, N., Smith, A. D., Morgan, S. J., Courtneidge, S. A., Parker, P. J., and Waterfield, M. D. (1991) Cell 65, 91-104 [Medline] [Order article via Infotrieve]
  2. Hiles, I. D., Otsu, M., Volinia, S., Fry, M. J., Gout, I., Dhand, R., Panayotou, G., Ruiz-Larrea, F., Thompson, A., Totty, N. F., Hsuan, J. J., Courtneidge, S. A., Parker, P. J., and Waterfield, M. D. (1992) Cell 70, 419-429 [Medline] [Order article via Infotrieve]
  3. Escobedo, J. A., Navankasattusas, S., Kavanaugh, W. M., Milfay, D., Fried, V. A., and Williams, L. T. (1991) Cell 65, 75-82 [Medline] [Order article via Infotrieve]
  4. Skolnik, E. Y., Margolis, B., Mohammadi, M., Lowenstein, E., Fischer, R., Drepps, A., Ullrich, A., and Schlessinger, J. (1991) Cell 65, 83-90 [Medline] [Order article via Infotrieve]
  5. Hu, P., Mondino, A., Skolnik, E. Y., and Schlessinger, J. (1993) Mol. Cell. Biol. 13, 7677-7688 [Abstract]
  6. Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., and Soltoff, S. (1991) Cell 64, 281-302 [Medline] [Order article via Infotrieve]
  7. Backer, J. M., Myers, M. G., Jr., Shoelson, S. E., Chin, D. J., Sun, X. J., Miralpeix, M., Hu, P., Margolis, B., Skolnik, E. Y., Schlessinger, J., and White, M. F. (1992) EMBO J. 11, 3469-3479 [Abstract]
  8. Carpenter, C. L., Auger, K. R., Chanudhuri, M., Yoakim, M., Schaffhausen, B., Shoelson, S., and Cantley, L. C. (1993) J. Biol. Chem. 268, 9478-9483 [Abstract/Free Full Text]
  9. Pleiman, C. M., Hertz, W. M., and Cambier, J. C. (1994) Science 263, 1609-1612 [Medline] [Order article via Infotrieve]
  10. Zhang, J., King, W. G., Dillon, S., Hall, A., Feig, L., and Rittenhouse, S. E. (1993) J. Biol. Chem. 268, 22251-22254 [Abstract/Free Full Text]
  11. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. (1994) Nature 370, 527-532 [CrossRef][Medline] [Order article via Infotrieve]
  12. Auger, K. R., Serunian, L. A., Soltoff, S. P., Libby, P., and Cantley, L. C. (1989) Cell 57, 167-175 [Medline] [Order article via Infotrieve]
  13. Nakanishi, H., Brewer, K. A., and Exton, J. H. (1993) J. Biol. Chem. 268, 13-16 [Abstract/Free Full Text]
  14. Toker, A., Meyer, M., Reddy, K. K., Falck, J. R., Aneja, R., Aneja, S., Parra, A., Burns, D. J., Ballas, L. M., and Cantley, L. C. (1994) J. Biol. Chem. 269, 32358-32367 [Abstract/Free Full Text]
  15. Dhand, R., Hiles, I., Panayotou, G., Roche, S., Fry, M. J., Gout, I., Totty, N. F., Truong, O., Vicendo, P., Yonezawa, K., Kasuga, M., Courtneidge, S. A., and Waterfield, M. D. (1994) EMBO J. 13, 522-533 [Abstract]
  16. Volinia, S., Dhand, R., Vanhaesebroeck, B., MacDougall, L. K., Stein, R., Zvelebil, M. J., Domin, J., Panaretou, C., and Waterfield, M. D. (1995) EMBO J. 14, 3339-3348 [Abstract]
  17. Stephens, L., Smrckq, A., Cooke, F. T., Jackson, T. R., Sternweis, P. C., and Hawkins, P. T. (1994) Cell 77, 83-93 [Medline] [Order article via Infotrieve]
  18. Stoyanov, B., Volinia, S., Hanck, T., Rubio, I., Loubtchenkov, M., Malek, D., Stoyanova, S., Vanhaesebroeck, B., Dhand, R., Nurnberg, B., Gierschik, P., Seedorf, K., Hsuan, J. J., Waterfield, M. D., and Wetzker, R. (1995) Science 269, 690-693 [Medline] [Order article via Infotrieve]
  19. Herman, P. K., Stack, J. H., and Emr, S. D. (1992) Trends Cell Biol. 2, 363-368 [Medline] [Order article via Infotrieve]
  20. Schu, P. V., Takegawa, K., Fry, M. J., Stack, J. H., Waterfield, M. D., and Emr, S. D. (1993) Science 260, 88-91 [Medline] [Order article via Infotrieve]
  21. Stack, J. H., and Emr, S. D. (1994) J. Biol. Chem. 269, 31552-31562 [Abstract/Free Full Text]
  22. Kodaki, T., Woscholski, R., Emr, S., Waterfield, M. D., Nurse, P., and Parker, P. J. (1994) Eur. J. Biochem. 219, 775-780 [Abstract]
  23. Joly, M., Kazlauskas, A., and Corvera, S. (1995) J. Biol. Chem. 270, 13225-13230 [Abstract/Free Full Text]
  24. Nishimura, R., Li, W., Kashishian, A., Mondino, A., Zhou, M., Cooper, J., and Schlessinger, J. (1993) Mol. Cell. Biol. 13, 6889-6896 [Abstract]
  25. Clarke, J. F., Young, P. W., Yonezawa, K., Kasuga, M., and Holman, G. D. (1994) Biochem. J. 300, 631-635 [Medline] [Order article via Infotrieve]
  26. Yano, H., Nakanishi, S., Kimura, K., Hanai, N., Saitoh, Y., Fukui, Y., Nonomura, Y., and Matsuda, Y. (1993) J. Biol. Chem. 268, 25846-25856 [Abstract/Free Full Text]
  27. Thelen, M., Wymann, M. P., and Langen, H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4960-4964 [Abstract]
  28. Arcaro, A., and Wymann, M. P. (1993) Biochem. J. 296, 297-301 [Medline] [Order article via Infotrieve]
  29. Cheatham, B., Vlahos, C. J., Cheatham, L., Wang, L., Blenis, J., and Kahn, C. R. (1994) Mol. Cell. Biol. 14, 4902-4911 [Abstract]
  30. Lee, A. D., Hansen, P. A., and Holloszy, J. O. (1995) FEBS Lett. 361, 51-54 [CrossRef][Medline] [Order article via Infotrieve]
  31. Yeh, J.-I., Gulve, E. A., Rameh, L., and Birnbaum, M. J. (1995) J. Biol. Chem. 270, 2107-2111 [Abstract/Free Full Text]
  32. Nakanishi, S., Catt, K. J., and Balla, T. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5317-5321 [Abstract]
  33. McGraw, T. E., Pytowski, B., Arzt, J., and Ferrone, C. (1991) J. Cell Biol. 112, 853-861 [Abstract]
  34. Ullrich, A., Bell, J. R., Chen, E. Y., Herrera, R., Petruzzelli, L. M., Dull, T. J., Gray, A., Coussens, L., Liao, Y.-C., Tsubokawa, M., Mason, A., Seeburg, P. H., Grunfeld, C., Rosen, O. M., and Ramachandran, J. (1985) Nature 313, 756-761 [Medline] [Order article via Infotrieve]
  35. White, M. F., Livingston, J. N., Backer, J. M., Lauris, V., Dull, T. J., Ullrich, A., and Kahn, C. R. (1988) Cell 54, 641-649 [Medline] [Order article via Infotrieve]
  36. Wiley, H. S., and Cunningham, D. D. (1982) J. Biol. Chem. 257, 4222-4229 [Free Full Text]
  37. Backer, J. M., Shoelson, S. E., Haring E., and White, M. F. (1991) J. Cell Biol. 115, 1535-1545 [Abstract]
  38. Dunn, K. W., McGraw, T. E., and Maxfield, F. R. (1989) J. Cell Biol. 109, 3303-3314 [Abstract]
  39. Kielian, M. C., and Helenius, A. (1984) J. Virol. 52, 281-283 [Medline] [Order article via Infotrieve]
  40. Kielian, M., Jungerwirth, S., Sayad, K. U., and DeCandido, S. (1990) J. Virol. 64, 4614-4624 [Medline] [Order article via Infotrieve]
  41. Phalen, T., and Kielian, M. (1991) J. Cell Biol. 112, 615-623 [Abstract]
  42. Duffus, W. A., Levy-Mintz, P., Klimjack, M. R., and Kielian, M. (1995) J. Virol. 69, 2471-2479 [Abstract]
  43. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  44. Rosenwald, A. G., Machamer, C. E., and Pagano, R. E. (1992) Biochemistry 31, 3581-3590 [Medline] [Order article via Infotrieve]
  45. Richo, G. R., and Conner, G. E. (1994) J. Biol. Chem. 269, 14806-14812 [Abstract/Free Full Text]
  46. Watts, C. (1985) J. Cell Biol. 100, 633-637 [Abstract]
  47. Carpentier, J. L., Paccaud, J. P., Gorden, P., Rutter, W. J., and Orci, L. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 162-166 [Abstract]
  48. Goncalves, E., Yamada, K., Thatte, H. S., Backer, J. M., Golan, D. E., Kahn, C. R., and Shoelson, S. E. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5762-5766 [Abstract]
  49. Marsh, M., and Helenius, A. (1989) Adv. Virus Res. 36, 107-151 [Medline] [Order article via Infotrieve]
  50. Strous, G. J. A. M., and Lodish, H. F. (1980) Cell 22, 709-717 [Medline] [Order article via Infotrieve]
  51. deCurtis, I., and Simons, K. (1988) Proc. Natl. Acad. Sci. U. S. A. 852, 8052-8056
  52. Kornfeld, S. (1987) FASEB J. 1, 462-468 [Abstract/Free Full Text]
  53. Dong, J. M., Prence, E. M., and Sahagian, G. G. (1989) J. Biol. Chem. 264, 7377-7383 [Abstract/Free Full Text]
  54. Brown, W. J., DeWald, D. B., Emr, S. D., Plutner, H., and Balch, W. E. (1995) J. Cell Biol. 130, 781-796 [Abstract]
  55. Davidson, H. W. (1995) J. Cell Biol. 130, 797-805 [Abstract]
  56. Braulke, T., Geuze, H. J., Slot, J. W., Hasilik, A., and von Figura, K. (1987) Eur. J. Cell Biol. 43, 316-321 [Medline] [Order article via Infotrieve]
  57. Nakanishi, S., Kakita, S., Takahashi, I., Kawahara, K., Tsukuda, E., Sano, T., Yamada, K., Yoshida, M., Kase, H., Matsuda, Y., Hashimoto, Y., and Nonomura, Y. (1992) J. Biol. Chem. 267, 2157-2163 [Abstract/Free Full Text]
  58. Powis, G., Bonjouklian, R., Berggren, M. M., Gallegos, A., Abraham, R., Ashendel, C., Zalkow, L., Matter, W. F., Dodge, J., Grindey, G., and Vlahos, C. J. (1994) Cancer Res. 54, 2419-2423 [Abstract]
  59. Woscholski, R., Kodaki, T., McKinnon, M., Waterfield, M. D., and Parker, P. J. (1994) FEBS Lett. 342, 109-114 [CrossRef][Medline] [Order article via Infotrieve]
  60. Beck, K. A., and Keen, J. H. (1991) J. Biol. Chem. 266, 4442-4447 [Abstract/Free Full Text]
  61. Goldschmidt-Clermont, P. J., Machesky, L. M., Baldessare, J. J., and Pollard, T. D. (1990) Science 247, 1575-1578 [Medline] [Order article via Infotrieve]
  62. Hay, J. C., Fisette, P. L., Jenkins, G. H., Fukami, K., Takenawa, T., Anderson, R. A., and Martin, T. F. (1995) Nature 374, 173-177 [CrossRef][Medline] [Order article via Infotrieve]
  63. Harlan, J. E., Hajduk, P. J., Yoon, H. S., and Fesik, S. W. (1994) Nature 371, 168-170 [CrossRef][Medline] [Order article via Infotrieve]
  64. Presley, J. F., Mayor, S., Dunn, K. W., Johnson, L. S., McGraw, T. E., and Maxfield, F. R. (1993) J. Cell Biol. 122, 1231-1241 [Abstract]
  65. Johnson, L. S., Dunn, K. W., Pytowski, B., and McGraw, T. E. (1993) Mol. Biol. Cell 4, 1251-1266 [Abstract]
  66. Li, G., D'Souza-Schorey, C., Barbieri, M. A., Roberts, R. L., Klippel, A., Williams, L. T., and Stahl, P. D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10207-10211 [Abstract]
  67. Marsh, E. W., Leopold, N. L., Jones, N. L., and Maxfield, F. R. (1995) J. Cell Biol. 129, 1509-1522 [Abstract]
  68. Weigel, P. H. (1992) in Glycoconjugates (Allen, H. J., and Kisailus, E. C., eds) pp. 421-498, Marcel Dekker, Inc., New York
  69. Stockert, R. J., Potvin, B., Tao, L., Stanley, P., and Wolkoff, A. W. (1995) J. Biol. Chem. 270, 16107-16113 [Abstract/Free Full Text]
  70. Endemann, G., Yonezawa, K., and Roth, R. A. (1990) J. Biol. Chem. 265, 396-400 [Abstract/Free Full Text]
  71. Ruderman, N., Kapeller, R., White, M. F., and Cantley, L. C. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1411-1415 [Abstract]
  72. Kapeller, R., Chem, K. S., Yoakim, M., Schaffhausen, B. S., Backer, J. M., White, M. F., Cantley, L. C., and Ruderman, N. B. (1991) Mol. Endocrinol. 5, 769-777 [Abstract]
  73. Backer, J. M., Shoelson, S. E., Weiss, M. A., Hua, Q. X., Cheatham, R. B., Haring, E., Cahill, D. C., and White, M. F. (1992) J. Cell Biol. 118, 831-839 [Abstract]
  74. Shepherd, P. R., Soos, M. A., and Siddle, K. (1995) Biochem. Biophys. Res. Commun. 211, 535-539 [CrossRef][Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.